沙库巴曲缬沙坦钠联合重组人尿激酶原治疗急性心肌梗死的效果及对心功能的影响

Effect of sacubitril valsartan sodium combined with recombinant human prourokinase in the treatment of acute myocardial infarction and its influence on cardiac function

目的探究沙库巴曲缬沙坦钠联合重组人尿激酶原治疗急性心肌梗死的效果及对心功能的影响。方法选择2020年2月至2023年3月收治的80例急性心肌梗死患者作为研究对象,根据入院时间将其分为对照组和观察组,各40例。对照组接受常规对症治疗结合重组人尿激酶原治疗,观察组在对照组基础上加施沙库巴曲缬沙坦钠治疗。比较两组的治疗效果。结果观察组的治疗总有效率高于对照组(P<0.05)。治疗后,观察组的左心室射血分数(LVEF)、心脏指数(CI)、每搏输出量(SV)大于对照组,左心室收缩末期内径(LVESD)小于对照组(P<0.05)。治疗后,观察组的N-末端脑钠肽前体(NT-proBNP)、肌红蛋白(Myo)、肌酸激酶同工酶(CK-MB)及心肌肌钙蛋白I(cTnI)水平低于对照组(P<0.05)。两组的不良反应总发生率无明显差异(P>0.05)。结论沙库巴曲缬沙坦钠联合重组人尿激酶原治疗急性心肌梗死的效果显著,不仅可缓解心肌损伤,改善心功能,且具有较高安全性,值得推广。

Objective To explore the effect of sacubitril valsartan sodium combined with recombinant human prourokinase in the treatment of acute myocardial infarction and its influence on cardiac function.Methods A total of 80 patients with acute myocardial infarction admitted from February 2020 to March 2023 were selected as the research objects.According to the time of admission,the patients were divided into control group and observation group,with 40 cases in each group.The control group was treated with conventional symptomatic treatment combined with recombinant human prourokinase,and the observation group was treated with sacubitril valsartan sodium on the basis of the control group.The therapeutic effects of the two groups were compared.Results The total effective rate of treatment in the observation group was higher than that in the control group(P<0.05).After treatment,the left ventricular ejection fraction(LVEF),cardiac index(CI)and stroke volume(SV)in the observation group were bigger than those in the control group,and the left ventricular end-systolic diameter(LVESD)was smaller than that in the control group(P<0.05).After treatment,the levels of N-terminal pro-brain natriuretic peptide(NT-proBNP),myoglobin(Myo),creatine kinase MB isoenzyme(CK-MB)and cardiac troponin I(cTnI)in the observation group were lower than those in the control group(P<0.05).There was no significant difference in the total incidence of adverse reactions between the two groups(P>0.05).Conclusion The sacubitril valsartan sodium combined with recombinant human prourokinase in the treatment of acute myocardial infarction has a significant effect.It can not only alleviate myocardial injury and improve cardiac function,but also has high safety,which is worthy of promotion.